Share on LinkedInShare on LinkedIn

ARTICLE · 23 JULY 2021

A Guiding Light For The Research Safe Harbor And "Research Tools"?

Proskauer Rose LLP
Proskauer Rose LLP
Contributor
Proskauer Rose LLP

Proskauer Rose LLP

Firm Overview Proskauer is an elite global law firm with more than 900 lawyers across key financial...

View firm profile
Explore more from Proskauer Rose LLP

Allele v. Pfizer – The Basics. On April 23, 2021 Pfizer, Inc., BioNTechSE, and BioNTech US, Inc. filed a joint reply supporting of their previously filed motion to dismiss a patent infringement complaint ...

United StatesIntellectual Property

Allele v. Pfizer - The Basics. On April 23, 2021 Pfizer, Inc., BioNTechSE, and BioNTech US, Inc. ("Pfizer and BioNTech") filed a joint reply supporting of their previously filed motion to dismiss a patent infringement complaint filed by Allele Biotechnology and Pharmaceuticals, Inc. ("Allele") in the Southern District of California. The patent at the center of the case is U.S. Pat. No. 10,221,221 ("the '221 Patent") which covers Allele's mNeonGreen, a monomeric yellow-green fluorescent protein notable for its intense brightness. On May 4, 2021, the court denied the motion to dismiss, leaning heavily of the Federal Circuit's 2008 decision Proveris Science Corp. v. Innovasystems, Inc. As this case continues to develop it could help shed light on an unsettled issue - are "research tools" categorically excluded from the 35 U.S.C. § 271(e)(1) Safe Harbor?

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from